App-Quantinova.ai

Identification of microRNA upregulated in pediatric precursor-B cell acute lymphoblastic leukemia patients with post-induction MRD positivity

Andrea Bauchat - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell anti-tumor efficacy and durability of response

Paul-Joseph Aspuria - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Interleukin

Increased epigenetic plasticity and tumor heterogeneity predict resistance to CD19 CAR T cell therapy in pre-treatment pediatric acute lymphoblastic leukemia

Katherine E. Masih - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Selective targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells

Inge Van der Werf - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

FD-895

The XPO1 inhibitior, eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes

Richard B. Lock - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Tacc1 is amplified in a wide range of pediatric malignancy

Aditya Rajan - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Investigating the role of the oncogenic miR-17-92 cluster as involved in TKI-resistance enhancing the survival of MYB-dependent Ph+ acute lymphoblastic leukemia cells

Manuela Spagnuolo - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

Immunoproteasome inhibitors for the treatment of ALL

Tyler W. Jenkins - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

carfilzomib Intravenous

Genetic screens reveal dependencies and chemotherapy modulators in NSD2-driven hematologic malignancies

Amin Sobh - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Glucocorticoid

A novel, potent and selective oral inhibitor of MEK1/2 for the treatment of solid tumors

Shu Lin - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Trametinib

Isatuximab based combinations induce potent tumor growth inhibition in pre-clinical models of multiple myeloma and acute lymphocytic leukemia

Chen Zhu - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

Repurposing the anti-depressant sertraline to target serine/glycine synthesis addicted cancer

Shauni L. Geeraerts - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Sertraline

Application of BET/CBP/p300 multi-bromodomain inhibitors as a novel therapeutic strategy for MLL-rearranged acute lymphoblastic leukemia

Natsuki Imayoshi - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Birabresib

Generation and characterization of human placental-derived CD19 CAR-T cells using viral vectors

Kathy Karasiewicz - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an in Vitro model of a High-Risk Acute Lymphoblastic Leukemia

Charlotte EJ Downes - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Ruxolitinib phosphate

First-in-Class Autologous CD7-CAR-T Cells Exhibited Promising Clinical Efficacy for Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

Mingzhi Zhang - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study

Lori Muffly - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia

Michael W Boyer - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

tisagenlecleucel-t

Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Blinatumomab

Prognostic Analyses for Adult Relapsed / Refractory Acute Lymphoblastic Leukemia Patients Who Received First Allogenic Hematopoietic Stem Cell Transplantation

Momoko Nakamura - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Allopurinol

Filters

2187 Abstracts